Conference Reports for NATAP

Back

The International Liver Congress™ EASL - European Association for the Study of the Liver June 23-26 2021     Persistent long-term risk of liver related complications in HCV patients after antiviral therapy - Data from the German Hepatitis C-Registry - (07/26/21)   IAS: HCV Reinfection Rate Almost 4% in Global Analysis of People With HIV - Mark Mascolini (07/26/21)   IAS: Drug Injecting Remains Barrier to HCV Elimination in Netherlands - Mark Mascolini (07/26/21)   IAS: HCV Cure Rate 92% in Hard-to-Reach Vietnam Drug-Injecting Group - Mark Mascolini (07/26/21)   IAS: HCV Reinfection Rate Almost 4% in Global Analysis of People With HIV - Mark Mascolini (07/25/21)   IAS: Drug Injecting Remains Barrier to HCV Elimination in Netherlands - Mark Mascolini (07/25/21)   IAS: HCV Cure Rate 92% in Hard-to-Reach Vietnam Drug-Injecting Group - Mark Mascolini (07/25/21)   Summary from EASL 2021 for Hepatitis B, C, D and fatty liver disease. Liver disease in 2021: advances and remaining challenges. Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (07/25/21)   Combinations of an Acetyl Coenzyme-A Carboxylase Inhibitor, FXR Agonist, and GLP-1R Agonist Inhibit Fibrosis Progression in the Rat Choline-Deficient, L-Amino-Acid-Defined, High-Fat Diet Model of Advanced Fibrosis - (07/14/21)   The Impact of COVID-19 Pandemic on Patients with Chronic Liver Disease (CLD): Data from the Global Registry - (07/12/21)   Liver Stiffness by Vibration-Controlled Transient Elastography Predicts Disease Progression in Patients With Advanced Fibrosis Due to NASH - (07/12/21)   AI-based histologic measurement of NASH (AIM-NASH): A drug development tool for assessing clinical trial endpoints - (07/12/21)   INCIDENCE OF LIVER AND NON-LIVER RELATED EVENTS AND MORTALITY IN A LARGE COHORT OF HCV CIRRHOTICS WITH AN SVR TO DAA: A 5-YEAR SINGLE CENTER STUDY - (07/12/21)   Free-immunoglobulin alternative strategy to prevent HBV mother-to-child transmission in Cambodia: the ANRS 12345 TA-PROHM study - (07/10/21)   Current or Past HBV Not Tied to Death With COVID in Hong Kong - Mark Mascolini (07/10/21)   Noninvasive Tools Can Spot Liver Transplant Patients With No Alloimmune Damage - Mark Mascolini (07/09/21)   Trimming FAST Score 0.2 Points Improves NASH Over 72 Weeks - Mark Mascolini (07/09/21)   Lower Response to Pfizer COVID Vaccine in Older People With Advanced Fibrosis - Mark Mascolini (07/09/21)   New FibroScan Score Improves Advanced Fibrosis Detection in NAFLD - Mark Mascolini (07/09/21)   THE ALARMING IMPACT OF COVID-19 PANDEMIC ON ALCOHOL-RELATED LIVER DISEASE: A POPULATION-BASED CANADIAN STUDY (07/08/21)   Hepatitis C in Connecticut Community Health Centers: Measuring the Impact of the project ECHO model on treatment in primary care (07/08/21)   A tailored program for screening, improved access to care and prioritization of treatment for PWUD with HCV chronic infection (07/08/21)   No Change in Alcoholic Cirrhosis Mortality in 20 Years-But Causes of Death Shift - Mark Mascolini (07/07/21)   Alcohol Dependence More Frequent in UK Inpatients During Than Before COVID - Mark Mascolini (07/07/21)   Simplified test and treat protocols for population level screening and elimination of hepatitis B and hepatitis C in Uzbekistan (07/07/21)   Beating Hepatitis C together in challenging times: an evaluation of a multi-disciplinary approach to testing and treating homeless people temporarily housed during the COVID-19 pandemic (07/06/21)   Mortality risk following HCV cure among people with HCV/HIV co-infection (07/06/21)   Is the Gender of Hepatitis C Patients Influencing Rapid Direct-acting Antiviral Treatment Start? Results from a Large Multinational Real-world Dataset (07/06/21)   Is the Age of Hepatitis C Patients Influencing Rapid Direct-acting Antiviral Treatment Start? Results from a Large multinational Real-world Dataset (07/06/21)   NASH Fibrosis Rate 2% in General Population of Spain-1.3% With Treatable Fibrosis - Mark Mascolini (07/05/21)   Fibrosis, Liver Markers Improve in F4 NASH With Once-Weekly Efruxifermin - Mark Mascolini (07/05/21)   Cilofexor and Firsocostat Treatment Is Associated With Widespread Changes in the Hepatic Transcriptome in NASH Patients With Advanced Fibrosis - (07/05/21)   Higher Risk of Liver Events, Nonliver Cancer, Death With Lean vs Nonlean NAFLD - Mark Mascolini (07/05/21)   About 2-Fold Higher Risk of MI, HCC, CKD When NASH Patients Have Cirrhosis - Mark Mascolini (07/05/21)   Higher Risk of Liver Events, Nonliver Cancer, Death With Lean vs Nonlean NAFLD - Mark Mascolini (07/05/21)   About 2-Fold Higher Risk of MI, HCC, CKD When NASH Patients Have Cirrhosis - Mark Mascolini (07/05/21)   Is the Age of Hepatitis C Patients Influencing Rapid Direct-acting Antiviral Treatment Start? Results from a Large multinational Real-world Dataset - (07/03/21)   The road to HCV elimination: entering the final stretch or chasing a moving finish line? - (07/03/21)   Safety and Efficacy of Bulevirtide Monotherapy and in Combination with Peginterferon Alfa-2a in Patients with Chronic Hepatitis Delta: 24 Weeks Interim Data of MYR204 Phase 2b Study - (07/03/21)   High rates of hidden HCV infections among hospitalized patients aged 55-85 - (07/02/21)   Improvement of all HCV care cascade steps in IVDU treated with DAAs within a dedicated program - (07/02/21)   Cost-effectiveness of a Core Antigen Based Rapid Diagnostic Test for Hepatitis C - (07/02/21)   From screening to therapy: Anti-HCV screening and linkage to care in a network of general practitioners and a private gastroenterology practice - (07/02/21)   Prevalence of non-alcoholic fatty liver in The Netherlands: the Netherlands Epidemiology of Obesity study - (06/29/21)   Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: week 48 follow-up results HBV Functional Cure Candidate, an siRNA, Passes Phase 2 Test of Activity - (06/29/21)   Hepatitis C Elimination in the Netherlands (CELINE): nationwide retrieval of lost to follow-up chronic hepatitis C patients - (06/28/21)   Anticipated timing of hepatitis C virus elimination in the Netherlands and the impact of COVID-19 - (06/28/21)   Phase 1 Results for ATI-2173, a Novel Active Site Polymerase Inhibitor Nucleotide (ASPIN), in HBV-Infected Subjects - (06/28/21)   Treatment with GSK3228836 leads to HBsAg reduction and induction of interferon gamma related proteins and chemokines in a Phase 2a, randomized, double-blind, placebo-controlled study - (06/28/21)   Single Dose of Monoclonal Antibody Quickly Cuts HBsAg in Phase 1 Trial - Mark Mascolini (06/28/21)   Second-generation hepatitis B virus core inhibitors ABI-H2158 and ABI-H3733 have enhanced potency and target coverage for both antiviral inhibition and covalently closed circular DNA establishment activities - (06/28/21)   Preclinical antiviral profile of AB-836, a potent, highly selective hepatitis B virus capsid inhibitor - (06/28/21)   Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression - (06/27/21)   Short interfering RNA JNJ-3989 combination therapy - Mark Mascolini (06/27/21)   IMPROVING THE ACCURACY OF NON-INVASIVE TESTS FOR PREDICTION OF CIRRHOSIS IN CHRONIC HEPATITIS DELTA: INSIGHTS FROM 230 PATIENTS OF THE D-LIVR STUDY - (06/27/21)   Safety and Efficacy of Bulevirtide Monotherapy and in Combination with Peginterferon Alfa-2a in Patients with Chronic Hepatitis Delta: 24 Weeks Interim Data of MYR204 Phase 2b Study - Mark Mascolini (06/27/21)   TDF-Based Hep B Immunoglobulin-Free Strategy Stalls HBV MTCT - (06/27/21)   Bulevirtide With or Without PEG-IFN Shows 24-Week Activity Against Hep D - Mark Mascolini (06/27/21)   New WHO Guidance on Viral Hepatitis Elimination - (06/26/21)   NAFLD Doubles Risk of CVD and Cuts up to 6 Years off Life Expectancy - Mark Mascolini (06/26/21)   Liver Impairment With COVID-19 Tied to More Severe Coronavirus Disease - Mark Mascolini (06/26/21)   Late Entry to Care in Almost Half of People With Chronic HCV in France - Mark Mascolini (06/26/21)   Frequency and impact of potential multiple drug-drug interactions (DDIs) associated with pangenotypic direct-acting antivirals in patients receiving opioid substitution therapy - (06/26/21)   Risk of multiple drug-drug interactions (DDIs) in HCV patients receiving pangenotypic DAAs (pDAAs): A complex drug interaction scenario first time evaluated in German patients - (06/26/21)   VALUE ASSESSMENT OF SOFOSBUVIR-BASED REGIMENS FOR (CHRONIC) HEPATITIS C IN SPAIN - (06/26/21)   Estimating the contribution of viral hepatitis and other etiologies to the burden of cirrhosis: a worldwide systematic review - (06/26/21)   Estimating the contribution of viral hepatitis and other etiologies to the burden of cirrhosis: a worldwide systematic review Together, HBV and HCV Less Prevalent in Cirrhosis Than in HCC Cases Worldwide - Mark Mascolini (06/26/21)   Long-term Efficacy and Safety of Tenofovir Disoproxil Fumarate in Children with Chronic Hepatitis B: Final Results from a Placebo-Controlled Trial - (06/25/21)   Safety and Efficacy of Oral TLR8 Agonist Selgantolimod in Viremic Adult Patients With Chronic Hepatitis B - (06/25/21)   Together, HBV and HCV Less Prevalent in Cirrhosis Than in HCC Cases Worldwide - Mark Mascolini (06/25/21)   Liver stiffness measurement for the prediction of liver-related outcomes in chronic hepatitis C patients after viral eradication - (06/25/21)   INCIDENCE OF LIVER AND NON-LIVER RELATED EVENTS AND MORTALITY IN A LARGE COHORT OF HCV CIRRHOTICS WITH AN SVR TO DAA: A 5-YEAR SINGLE CENTER STUDY....a reminder to treat early - (06/25/21)   Switching From Tenofovir Disoproxil Fumarate and/or Other Oral Antivirals to Tenofovir Alafenamide in Virally Suppressed Chronic Hepatitis B Patients With Hepatic Impairment: Final 2-Year Efficacy and Safety Results From a Phase 2 Open-label Study - (06/24/21)   Switching From Tenofovir Disoproxil Fumarate and/or Other Oral Antivirals to Tenofovir Alafenamide in Virally Suppressed Chronic Hepatitis B Patients With Moderate or Severe Renal Impairment, or With End-stage Renal Disease on Hemodialysis: Final Week-96 Efficacy and Safety Results From a Phase 2 Open-label Study - (06/24/21)   Concordance Between SVR4, SVR12, and SVR24 in HCV-Infected Patients Who Received Fixed-Dose Combination Sofosbuvir/Velpatasvir in Phase 3 Clinical Trials - (06/24/21)   Cost and Effectiveness of combining treatment on Day 1 (Rapid Start) for hepatitis C and higher screening effort in at-risk populations (T&T strategy) in France - (06/24/21)   Good practice hepatitis C screening and linkage to care initiatives at the SLTC Summit 2020: three out of four diagnosed patients were able to start direct-acting antiviral treatment - (06/24/21)   Bulevirtide Monotherapy at Low and High Doses in Patients With Chronic Hepatitis Delta: 24-Week Interim Data of the Phase 3 MYR301 Study - (06/24/21)   Chronic liver disease and risk of mortality after COVID-19: a national, retrospective, cohort study for 2020 - Mark Mascolini (06/24/21)   ASSOCIATION OF MAFLD WITH MORTALITY IN PATIENTS WITH COVID-19 IN MEXICO - (06/23/21)   A novel approach to age cohort screening for hepatitis C in the primary care setting of a large urban health care setting with linkage to care - (06/23/21)   DETECTION OF ACTIVE HEPATITIS C BY A TWO-STEP POINT-OF-CARE BASED STRATEGY AND LINK-TO-CARE AMONG EXCLUDED PEOPLE IN MADRID, SPAIN - (06/23/21)   Cirrhosis regression based on both Enhanced Liver Fibrosis (ELF) and Fibrotest after Direct-acting Hepatitis C therapeutics corresponds to a lower incidence rate of hepatocellular carcinoma below the cost-effective threshold for surveillance - (06/23/21)   Impact of the COVID-19 Pandemic on Hepatitis C Virus Screening in Drug Treatment Settings in England and Implications for Future Testing Protocols - (06/23/21)   Impact of direct-acting antiviral treatment on mortality related to extrahepatic manifestations: findings from a large population-based cohort in British Columbia, Canada - (06/23/21)   Modeling HCV elimination recovery following the COVID-19 pandemic in the United States: Pathways to regain progress - (06/23/21)   Prevalence and origin of rare HCV genotypes in DAA-naive and DAA-experienced patients - (06/23/21)   RAPID POINT OF CARE HCV TESTING ALLOWS HIGH VOLUME SCREENING AND RAPID TREATMENT UPTAKE AMONG PWID ATTENDING A MEDICALLY SUPERVISED INJECTING ROOM - (06/23/21)   Tenofovir May Trim COVID-19 Severity in People With Chronic HBV - Mark Mascolini - (06/23/21)   Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients With Signs of Portal Hypertension - (06/23/21)   COVID Impact on Global Liver Disease - press releases from EASL 2021 EASL press releases - (06/23/21)